Debra Patt, MD, PhD, MBA, executive vice president at Texas Oncology, explains the small potential risk of breast cancer associated with hormonal birth control.
Hormonal birth control carries risks of adverse events, as do all medications, and one association appears to be a very slightly increased risk of breast cancer, according to Debra Patt, MD, PhD, MBA, executive vice president, Texas Oncology.
Transcript
Should people be concerned over the recent study gaining media attention that hormonal birth control increases risk of breast cancer?
Sure, I think that with any drug that you take, you should always be cognizant of the desired effects and unintended side effects of any medication. For patients, hormonal contraception can very slightly, and I will say very slightly, increase the risk for breast cancer. We know that's a cumulative risk.
I think for every patient, like with any therapy, you need to carefully think about the effects that are desired in contrast to the potential side effects, because it's not a universal recommendation for every patient.
For example, if you have a patient that is just desiring a mechanism of contraception, and they have a very high breast cancer risk because of a genetic susceptibility or family members who've had breast cancer, for them, the decision might be very different than someone who has no family history of breast cancer and has contraindications to other forms of contraception. So, I think it varies per patient. But yes, it's a risk. But it's a very small risk.
Actually, I think that most patients take oral contraceptives safely without any increased risk for breast cancer. The truth is—and everyone asks, because breast cancer is common—if this caused it or that caused it, but breast cancer is just common; 1 out of 8 women will get breast cancer in their lifetime. So, the percentage of that risk that you can attribute to a history of oral contraceptive use is really quite small.
Age-Related Disparities in Long-Term Outcomes for ER+, HER2– Breast Cancer
November 23rd 2024Younger women with estrogen receptor (ER)–positive, HER2-negative breast cancer have significantly worse long-term outcomes, including higher rates of recurrence and metastasis, compared with older women.
Read More
Semaglutide Eligibility Expands to Over Half of US Adults
November 21st 2024Over half of the US adult population may benefit from semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications.
Read More
Racial Inequities in Guideline-Adherent Breast Cancer Care and Timely Treatment
November 19th 2024Older non-Hispanic Black adults with early-stage breast cancer are less likely to receive timely treatment and guideline-concordant care, increasing their risk of death compared with non-Hispanic White women.
Read More
Community Investment, Engagement Are Essential to Fully Address Cardiovascular Health Disparities
November 19th 2024Community-based researchers can teach clinicians a lot about how to best approach underserved populations disproportionately impacted by cardiovascular health complications.
Read More